The Global Bronchodilators Market size is expected to reach $27 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.
Bronchodilators are drugs that relax the muscles which tighten around the airways. These drugs open airways and allow more air to come and pass through the lungs and decrease mucus from the lungs. Patients suffering from various respiratory disorders take these drugs through nebulizers or inhalers. Also, inhaling bronchodilators have effects on mucociliary clearance too.
Bronchodilators are also utilized to treat obstructive lung diseases by relaxing the muscles in the lungs and widening the airways (bronchi). They also treat chronic obstructive pulmonary diseases (COPD) and asthma. The relaxation of the muscles in the airways due to the bronchodilators, opens them up and the bronchial tube to widen. They come in different types and each works in a slightly different way than the other. They are; beta 2-agonists, anticholinergics and xanthine derivatives (theophylline).
Beta-2 agonists are utilized for both COPD and asthma, but some beta-2 agonists are only recommended for patients with COPD. They are generally inhaled with the help of a small handheld inhaler but are available as syrups or tablets too. In case of sudden or severe symptoms, they can also be injected into the body or nebulized. A nebulizer is a compressor that changes the liquid medication into a fine mist. Beta-2 agonists work by stimulating receptors known as beta-2 receptors in the muscles that are in the airways, which causes them to relax and allow the airways to dilate.
Anticholinergics, also known as antimuscarinics, are majorly used for treating COPD, but in some cases, they can also be used to treat asthma. They are taken with the help of an inhaler, but nebulizing the medication is also available for sudden need. Anticholinergics cause the airway to dilate by blocking the cholinergic nerves. These nerves release a chemical that can force the muscles lining the airways to tighten up. Theophylline is generally taken in capsule or tablet form, but a different version called aminophylline can be given directly into the vein if the symptoms are severe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Bronchodilators are drugs that relax the muscles which tighten around the airways. These drugs open airways and allow more air to come and pass through the lungs and decrease mucus from the lungs. Patients suffering from various respiratory disorders take these drugs through nebulizers or inhalers. Also, inhaling bronchodilators have effects on mucociliary clearance too.
Bronchodilators are also utilized to treat obstructive lung diseases by relaxing the muscles in the lungs and widening the airways (bronchi). They also treat chronic obstructive pulmonary diseases (COPD) and asthma. The relaxation of the muscles in the airways due to the bronchodilators, opens them up and the bronchial tube to widen. They come in different types and each works in a slightly different way than the other. They are; beta 2-agonists, anticholinergics and xanthine derivatives (theophylline).
Beta-2 agonists are utilized for both COPD and asthma, but some beta-2 agonists are only recommended for patients with COPD. They are generally inhaled with the help of a small handheld inhaler but are available as syrups or tablets too. In case of sudden or severe symptoms, they can also be injected into the body or nebulized. A nebulizer is a compressor that changes the liquid medication into a fine mist. Beta-2 agonists work by stimulating receptors known as beta-2 receptors in the muscles that are in the airways, which causes them to relax and allow the airways to dilate.
Anticholinergics, also known as antimuscarinics, are majorly used for treating COPD, but in some cases, they can also be used to treat asthma. They are taken with the help of an inhaler, but nebulizing the medication is also available for sudden need. Anticholinergics cause the airway to dilate by blocking the cholinergic nerves. These nerves release a chemical that can force the muscles lining the airways to tighten up. Theophylline is generally taken in capsule or tablet form, but a different version called aminophylline can be given directly into the vein if the symptoms are severe.
COVID-19 Impact Analysis
COVID-19 has impacted the bronchodilators market in the starting phase due to the lockdowns by many nations with the denied COPD and asthma treatment due to the given importance to COVID-19 patients. Because of the halt in the supply chain, there was a shortage of bronchodilator medications. Many bronchodilators manufacturing companies were forced to stop their production due to the pandemic and labor shortage. Furthermore, business operations were halted due to the new government regulations, which directly influenced the companies' revenue in the bronchodilators market.Market Growth Factors
Increasing air pollution across the globe
Motor vehicles, household combustion, forest fires, and industrial facilities are familiar air pollution sources. Pollutants of primary public health concern contain particulate matter, carbon monoxide, ozone, sulfur dioxide, and nitrogen. Indoor and outdoor air pollution cause respiratory and other diseases and are significant factors for mortality and morbidity. According to World Health Organization, almost all of the world's population breathes air that exceeds WHO guideline limits and has high levels of pollutants. Out of that, low and middle-income countries are suffering from the highest exposures.Surging number of geriatric populations
According to WHO, one in every six people in the world will be aged 60 years or over by 2030. The share of the world’s population aged 60 years and above will rise from 1 billion in 2020 to 1.4 billion. The world’s population of people aged 60 years and older will double to around 2.1 billion, and the 80 years old will triple to 426 million between 2020 and 2050. While this shift in the distribution of a country’s population towards the older ages, called population aging, has already started in high-income nations, it is now experiencing the most significant change in low- and middle-income countries. By 2050, two-thirds of the world’s population will be over 60 years old and in low- or middle-income countries.Market Restraining Factor
High cost of imaging equipment
A chest X-ray can aid in assisting the diagnosis of many lung diseases and rule out other causes of shortness of breath. Various hospitals in developing nations cannot invest in diagnostic imaging equipment due to high costs and financial restrictions. Many hospitals that cannot buy new cutting-edge imaging systems instead opt to utilize rebuilt imaging systems because of the high demand for diagnostics procedures, especially in low-income countries.Drug Class Outlook
Based on drug class, the bronchodilators market is segmented into beta-adrenergic, xanthine derivatives and anticholinergic. The anticholinergic segment acquired a promising growth rate in the bronchodilators market in 2021. This is due to anticholinergics' availability in short- and long-acting formulations. These drugs prevent the parasympathetic nerve reflexes from airways constriction, which allows the airways to remain open.Route of Administration Outlook
On the basis of route of administration, the bronchodilators market is divided into oral, nasal (inhalable) and injectable. The oral segment procured a prominent revenue share in the bronchodilator market in 2021. This is because many patients and clinicians prefer to avoid the adverse effects of injectables administration. Also, they are less costly than many generic substitutes and have many advantages like non-invasiveness, the convenience of drug administration, and patient compliance.Disease Outlook
By disease, the bronchodilators market is classified into asthma, chronic obstructive pulmonary disease (COPD) and others. The asthma segment witnessed the largest revenue share in the bronchodilator market in 2021. This is due to the rising prevalence of asthma among the population. In addition, there is a robust research and development pipeline with many mid or late-stage development organizations.Regional Outlook
Region-wise, the bronchodilators market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the bronchodilator market in 2021. The growth is due to the increasing demand for fast-acting and high-efficiency drugs. The surging COPD cases are due to air pollution, dust, working with chemicals, a history of childhood lung infection, and second-hand smoke. Also, there is a large number of smokers who are suffering from a smoke-related disease. The air pollution, high smoker count, and the rising number of old adults are expected to boost the bronchodilators market growth in the region.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Beta-Adrenergic
- Xanthine Derivatives
- Anticholinergic
By Route of Administration
- Nasal (Inhalable)
- Oral
- Injectable
By Disease
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
By Geography
North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd
- Cipla Limited
- Viatris, Inc
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Bronchodilators Market, by Drug Class
1.4.2 Global Bronchodilators Market, by Route of Administration
1.4.3 Global Bronchodilators Market, by Disease
1.4.4 Global Bronchodilators Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Bronchodilators Market by Drug Class
3.1 Global Beta-Adrenergic Market by Region
3.2 Global Xanthine Derivatives Market by Region
3.3 Global Anticholinergic Market by Region
Chapter 4. Global Bronchodilators Market by Route of Administration
4.1 Global Nasal (Inhalable) Market by Region
4.2 Global Oral Market by Region
4.3 Global Injectable Market by Region
Chapter 5. Global Bronchodilators Market by Disease
5.1 Global Asthma Market by Region
5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Bronchodilators Market by Region
6.1 North America Bronchodilators Market
6.1.1 North America Bronchodilators Market by Drug Class
6.1.1.1 North America Beta-Adrenergic Market by Country
6.1.1.2 North America Xanthine Derivatives Market by Country
6.1.1.3 North America Anticholinergic Market by Country
6.1.2 North America Bronchodilators Market by Route of Administration
6.1.2.1 North America Nasal (Inhalable) Market by Country
6.1.2.2 North America Oral Market by Country
6.1.2.3 North America Injectable Market by Country
6.1.3 North America Bronchodilators Market by Disease
6.1.3.1 North America Asthma Market by Country
6.1.3.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
6.1.3.3 North America Others Market by Country
6.1.4 North America Bronchodilators Market by Country
6.1.4.1 US Bronchodilators Market
6.1.4.1.1 US Bronchodilators Market by Drug Class
6.1.4.1.2 US Bronchodilators Market by Route of Administration
6.1.4.1.3 US Bronchodilators Market by Disease
6.1.4.2 Canada Bronchodilators Market
6.1.4.2.1 Canada Bronchodilators Market by Drug Class
6.1.4.2.2 Canada Bronchodilators Market by Route of Administration
6.1.4.2.3 Canada Bronchodilators Market by Disease
6.1.4.3 Mexico Bronchodilators Market
6.1.4.3.1 Mexico Bronchodilators Market by Drug Class
6.1.4.3.2 Mexico Bronchodilators Market by Route of Administration
6.1.4.3.3 Mexico Bronchodilators Market by Disease
6.1.4.4 Rest of North America Bronchodilators Market
6.1.4.4.1 Rest of North America Bronchodilators Market by Drug Class
6.1.4.4.2 Rest of North America Bronchodilators Market by Route of Administration
6.1.4.4.3 Rest of North America Bronchodilators Market by Disease
6.2 Europe Bronchodilators Market
6.2.1 Europe Bronchodilators Market by Drug Class
6.2.1.1 Europe Beta-Adrenergic Market by Country
6.2.1.2 Europe Xanthine Derivatives Market by Country
6.2.1.3 Europe Anticholinergic Market by Country
6.2.2 Europe Bronchodilators Market by Route of Administration
6.2.2.1 Europe Nasal (Inhalable) Market by Country
6.2.2.2 Europe Oral Market by Country
6.2.2.3 Europe Injectable Market by Country
6.2.3 Europe Bronchodilators Market by Disease
6.2.3.1 Europe Asthma Market by Country
6.2.3.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
6.2.3.3 Europe Others Market by Country
6.2.4 Europe Bronchodilators Market by Country
6.2.4.1 Germany Bronchodilators Market
6.2.4.1.1 Germany Bronchodilators Market by Drug Class
6.2.4.1.2 Germany Bronchodilators Market by Route of Administration
6.2.4.1.3 Germany Bronchodilators Market by Disease
6.2.4.2 UK Bronchodilators Market
6.2.4.2.1 UK Bronchodilators Market by Drug Class
6.2.4.2.2 UK Bronchodilators Market by Route of Administration
6.2.4.2.3 UK Bronchodilators Market by Disease
6.2.4.3 France Bronchodilators Market
6.2.4.3.1 France Bronchodilators Market by Drug Class
6.2.4.3.2 France Bronchodilators Market by Route of Administration
6.2.4.3.3 France Bronchodilators Market by Disease
6.2.4.4 Russia Bronchodilators Market
6.2.4.4.1 Russia Bronchodilators Market by Drug Class
6.2.4.4.2 Russia Bronchodilators Market by Route of Administration
6.2.4.4.3 Russia Bronchodilators Market by Disease
6.2.4.5 Spain Bronchodilators Market
6.2.4.5.1 Spain Bronchodilators Market by Drug Class
6.2.4.5.2 Spain Bronchodilators Market by Route of Administration
6.2.4.5.3 Spain Bronchodilators Market by Disease
6.2.4.6 Italy Bronchodilators Market
6.2.4.6.1 Italy Bronchodilators Market by Drug Class
6.2.4.6.2 Italy Bronchodilators Market by Route of Administration
6.2.4.6.3 Italy Bronchodilators Market by Disease
6.2.4.7 Rest of Europe Bronchodilators Market
6.2.4.7.1 Rest of Europe Bronchodilators Market by Drug Class
6.2.4.7.2 Rest of Europe Bronchodilators Market by Route of Administration
6.2.4.7.3 Rest of Europe Bronchodilators Market by Disease
6.3 Asia Pacific Bronchodilators Market
6.3.1 Asia Pacific Bronchodilators Market by Drug Class
6.3.1.1 Asia Pacific Beta-Adrenergic Market by Country
6.3.1.2 Asia Pacific Xanthine Derivatives Market by Country
6.3.1.3 Asia Pacific Anticholinergic Market by Country
6.3.2 Asia Pacific Bronchodilators Market by Route of Administration
6.3.2.1 Asia Pacific Nasal (Inhalable) Market by Country
6.3.2.2 Asia Pacific Oral Market by Country
6.3.2.3 Asia Pacific Injectable Market by Country
6.3.3 Asia Pacific Bronchodilators Market by Disease
6.3.3.1 Asia Pacific Asthma Market by Country
6.3.3.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
6.3.3.3 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Bronchodilators Market by Country
6.3.4.1 China Bronchodilators Market
6.3.4.1.1 China Bronchodilators Market by Drug Class
6.3.4.1.2 China Bronchodilators Market by Route of Administration
6.3.4.1.3 China Bronchodilators Market by Disease
6.3.4.2 Japan Bronchodilators Market
6.3.4.2.1 Japan Bronchodilators Market by Drug Class
6.3.4.2.2 Japan Bronchodilators Market by Route of Administration
6.3.4.2.3 Japan Bronchodilators Market by Disease
6.3.4.3 India Bronchodilators Market
6.3.4.3.1 India Bronchodilators Market by Drug Class
6.3.4.3.2 India Bronchodilators Market by Route of Administration
6.3.4.3.3 India Bronchodilators Market by Disease
6.3.4.4 South Korea Bronchodilators Market
6.3.4.4.1 South Korea Bronchodilators Market by Drug Class
6.3.4.4.2 South Korea Bronchodilators Market by Route of Administration
6.3.4.4.3 South Korea Bronchodilators Market by Disease
6.3.4.5 Singapore Bronchodilators Market
6.3.4.5.1 Singapore Bronchodilators Market by Drug Class
6.3.4.5.2 Singapore Bronchodilators Market by Route of Administration
6.3.4.5.3 Singapore Bronchodilators Market by Disease
6.3.4.6 Malaysia Bronchodilators Market
6.3.4.6.1 Malaysia Bronchodilators Market by Drug Class
6.3.4.6.2 Malaysia Bronchodilators Market by Route of Administration
6.3.4.6.3 Malaysia Bronchodilators Market by Disease
6.3.4.7 Rest of Asia Pacific Bronchodilators Market
6.3.4.7.1 Rest of Asia Pacific Bronchodilators Market by Drug Class
6.3.4.7.2 Rest of Asia Pacific Bronchodilators Market by Route of Administration
6.3.4.7.3 Rest of Asia Pacific Bronchodilators Market by Disease
6.4 LAMEA Bronchodilators Market
6.4.1 LAMEA Bronchodilators Market by Drug Class
6.4.1.1 LAMEA Beta-Adrenergic Market by Country
6.4.1.2 LAMEA Xanthine Derivatives Market by Country
6.4.1.3 LAMEA Anticholinergic Market by Country
6.4.2 LAMEA Bronchodilators Market by Route of Administration
6.4.2.1 LAMEA Nasal (Inhalable) Market by Country
6.4.2.2 LAMEA Oral Market by Country
6.4.2.3 LAMEA Injectable Market by Country
6.4.3 LAMEA Bronchodilators Market by Disease
6.4.3.1 LAMEA Asthma Market by Country
6.4.3.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country
6.4.3.3 LAMEA Others Market by Country
6.4.4 LAMEA Bronchodilators Market by Country
6.4.4.1 Brazil Bronchodilators Market
6.4.4.1.1 Brazil Bronchodilators Market by Drug Class
6.4.4.1.2 Brazil Bronchodilators Market by Route of Administration
6.4.4.1.3 Brazil Bronchodilators Market by Disease
6.4.4.2 Argentina Bronchodilators Market
6.4.4.2.1 Argentina Bronchodilators Market by Drug Class
6.4.4.2.2 Argentina Bronchodilators Market by Route of Administration
6.4.4.2.3 Argentina Bronchodilators Market by Disease
6.4.4.3 UAE Bronchodilators Market
6.4.4.3.1 UAE Bronchodilators Market by Drug Class
6.4.4.3.2 UAE Bronchodilators Market by Route of Administration
6.4.4.3.3 UAE Bronchodilators Market by Disease
6.4.4.4 Saudi Arabia Bronchodilators Market
6.4.4.4.1 Saudi Arabia Bronchodilators Market by Drug Class
6.4.4.4.2 Saudi Arabia Bronchodilators Market by Route of Administration
6.4.4.4.3 Saudi Arabia Bronchodilators Market by Disease
6.4.4.5 South Africa Bronchodilators Market
6.4.4.5.1 South Africa Bronchodilators Market by Drug Class
6.4.4.5.2 South Africa Bronchodilators Market by Route of Administration
6.4.4.5.3 South Africa Bronchodilators Market by Disease
6.4.4.6 Nigeria Bronchodilators Market
6.4.4.6.1 Nigeria Bronchodilators Market by Drug Class
6.4.4.6.2 Nigeria Bronchodilators Market by Route of Administration
6.4.4.6.3 Nigeria Bronchodilators Market by Disease
6.4.4.7 Rest of LAMEA Bronchodilators Market
6.4.4.7.1 Rest of LAMEA Bronchodilators Market by Drug Class
6.4.4.7.2 Rest of LAMEA Bronchodilators Market by Route of Administration
6.4.4.7.3 Rest of LAMEA Bronchodilators Market by Disease
Chapter 7. Company Profiles
7.1 Glenmark Pharmaceuticals Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.1.4 Recent strategies and developments:
7.1.4.1 Product Launches and Product Expansions:
7.2 Merck & Co., Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 GlaxoSmithKline PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 AstraZeneca PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Cipla Limited
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.7 Viatris, Inc. (Mylan N.V.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.10. Sun Pharmaceutical Industries Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
Companies Mentioned
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Cipla Limited
- Viatris, Inc.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 203 |
| Published | January 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 20607.8 Million |
| Forecasted Market Value ( USD | $ 27023.8 Million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
